Current studentsExisting staffContact us
 

Misoprostol for induction of labour to terminate pregnancy in the second or third trimester for women with a fetal anomaly or after intrauterine fetal death

Simple item page
dc.contributor.authorDodd, J.
dc.contributor.authorCrowther, C.
dc.date.issued2010
dc.description.abstractBackground A woman may need to give birth prior to the spontaneous onset of labour in situations where the fetus has died in utero (also called a stillbirth), or for the termination of pregnancy where the fetus, if born alive would not survive or would have a permanent handicap. Misoprostol is a prostaglandin medication that can be used to induce labour in these situations. Objectives To compare the benefits and harms of misoprostol to induce labour to terminate pregnancy in the second and third trimester for women with a fetal anomaly or after intrauterine fetal death when compared with other methods of induction of labour. Search strategy We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (November 2009). Selection criteria Randomised controlled trials comparing misoprostol with placebo or no treatment, or any other method of induction of labour, for women undergoing induction of labour to terminate pregnancy in the second and third trimester following an intrauterine fetal death or for fetal anomalies. Data collection and analysis Both authors independently assessed trial quality and extracted data. Main results We included 38 studies (3679 women). Nine studies included pregnancies after intrauterine deaths, five studies included termination of pregnancies because of fetal anomalies when the fetus was still alive and the rest (24) presented the pooled data for intrauterine deaths, fetal anomalies and social reasons. When compared with agents that have traditionally been used to induce labour in this setting (for example, gemeprost, prostaglandin E2 and prostaglandin F2alpha), vaginal misoprostol is as effective in ensuring vaginal birth within 24 hours, with a similar induction to birth interval. Vaginal misoprostol is associated with a reduction in the occurrence of maternal gastrointestinal side effects such as nausea, vomiting and diarrhoea when compared with other prostaglandin preparations. While the different treatments involving various prostaglandin preparations appear comparable for the reported outcomes, the information available regarding rare maternal complications, such as uterine rupture, is limited.
dc.description.statementofresponsibilityJodie M Dodd and Caroline A Crowther
dc.identifier.citationCochrane Database of Systematic Reviews, 2010; 2010(4):004901-1-004901-122
dc.identifier.doi10.1002/14651858.CD004901.pub2
dc.identifier.issn1469-493X
dc.identifier.issn1361-6137
dc.identifier.orcidDodd, J. [0000-0002-6363-4874]
dc.identifier.orcidCrowther, C. [0000-0002-9079-4451]
dc.identifier.urihttp://hdl.handle.net/2440/61281
dc.language.isoen
dc.publisherUpdate Software Ltd
dc.rightsCopyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
dc.source.urihttps://doi.org/10.1002/14651858.cd004901.pub2
dc.subjectHumans
dc.subjectFetal Death
dc.subjectAbortifacient Agents, Nonsteroidal
dc.subjectOxytocics
dc.subjectMisoprostol
dc.subjectAbortion, Induced
dc.subjectLabor, Induced
dc.subjectPregnancy
dc.subjectPregnancy Trimester, Second
dc.subjectPregnancy Trimester, Third
dc.subjectFemale
dc.subjectCongenital Abnormalities
dc.subjectRandomized Controlled Trials as Topic
dc.titleMisoprostol for induction of labour to terminate pregnancy in the second or third trimester for women with a fetal anomaly or after intrauterine fetal death
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Obstetrics and Gynaecology publications